Sex-specific differences in the treatment of severe psoriasis

Journal of the American Academy of Dermatology

Volumn 42, Issue 4, 2000, Pages 620-623

  Hotard, Rachel S ^a   Feldman, Steven R ^a   Fleischer Jr , Alan B ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; ETRETINATE; ISOTRETINOIN; METHOTREXATE;

ADULT; ARTICLE; DRUG INDICATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHOTOCHEMOTHERAPY; PRESCRIPTION; PRIORITY JOURNAL; PSORIASIS; PUVA; SEX DIFFERENCE; TERATOGENESIS; TREATMENT INDICATION;

EID: 0033940689     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2000.101596     Document Type: Article

References (27)

1. Zug KA, Littenberg B, Baughman RD, Kneeland T, Nease RF, Sumner W, etal. Assessing the preferences of patients with psoriasis. Arch Dermatol 1995;131:561-8.
2. Feldman SR. Psoriasis treatment. Curr Probl Dermatol 1998; 10:1-40.
3. Roenigk RK, Roenigk HH Jr. Sex differences in the psychological effects of psoriasis. Cutis 1978;21:529-33.
4. McKenna KE, Stern RS. The impact of psoriasis on the quality of life of patients from the 16-center PUVA follow-up cohort. J Am Acad Dermatol 1997;36:388-97.
5. Nevitt GJ, Hutchinson PE. Psoriasis in the community: prevalence, severity, and patients' beliefs and attitudes towards the disease. Br J Dermatol 1996;135:533-7.
6. Schmid-Ott G, Jaeger B, Kuensebeck HW, Ott R, Lamprecht F. Dimensions of stigmatization in patients with psoriasis in a "Questionnaire on experience with skin complaints." Dermatology 1996;193:304-10.
7. Gupta MA, Gupta AK. Age and gender differences in the impact of psoriasis on quality of life. Int J Dermatol 1995;34:700-3.
8. Gupta MA, Gupta AK, Kirkby S, Weiner HK, Mace TM, Schork NJ, et al. Pruritus in psoriasis: a prospective study of some psychiatric and dermatologic correlates. Arch Dermatol 1988;124: 1052-7.
9. Gupta MA, Schork NJ, Gupta AK, Kirkby S, Ellis CN. Suicidal ideation in psoriasis, Int J Dermatol 1993;32:188-90.
10. Rapp SR, Exum ML, Reboussin DM, Feldman SR, Fleischer AB, Clark AR.The physical, psychological, and social impact of psoriasis. J Health Psychol 1997;2:525-37.
11. Fortune DG, Main CJ, O'Sullivan TM, Griffiths CE. Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress. Br J Dermatol 1997;137:755-60.
12. Fortune DG, Main CJ, O'Sullivan TM, Griffiths CE. Assessing illness-related stress in psoriasis: the psychometric properties of the psoriasis life stress inventory. J Psychosom Res 1997;42:467-75.
13. Lebwohl M, Tan MH. Psoriasis and stress [letter]. Lancet 1998;351:82.
14. Fleischer AB, Feldman SR, Rapp SR, Reboussin DM, Exum ML, Clark AR, et al. Disease severity measures in a population of psoriasis patients: the symptoms of psoriasis correlate with self-administered Psoriasis Area Severity Index scores. J Invest Dermatol 1996;107:26-9.
15. Physician's Desk Reference. 53rd ed. Montvale (NJ): Medical Economics Data Production Company; 1999. p. 1397-401.
16. Smith ES, Fleischer AB, Feldman SR. Nondermatologists are more likely than dermatologists to prescribe antifungal/ corticosteroid products: an analysis of office visits for cutaneous fungal infections 1990-1994. J Am Acad Dermatol 1998;39:43-7.
17. Physician ICD-9-CM; vol 1. Salt Lake City: Medicode Publications; 1997.
18. Stoughton RB. Vasoconstrictor assay-specific applications. In: Maibach HI, Surber C, editors.Topical corticosteroids. Basel, Switzerland: Karger; 1992. p. 42-53.
19. Safran DG, Rogers WH, Tarlov AR, McHorney CA, Ware JE Jr. Gender differences in medical treatment: the case of physician-prescribed activity restrictions. Soc Sci Med 1997;45:711-22.
20. Schulman KA, Berlin JA, Harless W, et al. The effect of race and sex on physicians' recommendations for cardiac catheterization. N Engl J Med 1999;340:618-26.
21. Garbis H, Elefant E, Bertolotti E, Robert E, Serafini MA, Prapas N. Pregnancy outcome after periconceptional and first-trimester exposure to methoxsalen photochemotherapy. Arch Dermatol 1995;131:492-3.
22. Gunnarskog JG, Kallen AJ, Lindelof BG, Sigurgeirsson B. Psoralen photochemotherapy (PUVA) and pregnancy. Arch Dermatol 1993;129:320-3.
23. Stern RS, Lange R. Outcomes of pregnancies among women and partners of men with a history of exposure to methoxsalen photochemotherapy (PUVA) for the treatment of psoriasis. Arch Dermatol 1991;127:347-50.
24. Modigliani R. Drug therapy for ulcerative colitis during pregnancy. Eur J Gastroenterol Hepatol 1997;9:854-7.
25. Ghandour FZ, Knauss TC, Hrick DE. Immunosuppressive drugs in pregnancy. Adv Ren Replace Ther 1998;5:31-7.
26. Picascia DD, Garden JM, Freinkel RK, et al.Treatment of resistant severe psoriasis with systemic cyclosporine. J Am Acad Dermatol 1987;17:408-14.
27. Ellis CN, Gorsulowsky DC, Hamilton TA, et al. Cyclosporine improves psoriasis in a double-blind study. JAMA 1986;256: 3110-6.